Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViiV IPO Plans Ditched By GSK; New Plan Is To Retain Value

This article was originally published in The Pink Sheet Daily

Executive Summary

The British health care company has decided not to spin out a minority stake in its fast-growing HIV joint venture, in part because of feedback from investors against the idea.

You may also be interested in...

ViiV’s Visibility Grows And Pressure Mounts For What Comes Next

GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.

Bristol Offloads HIV Pipeline To ViiV As It Tightens Focus

Deal brings GSK/Pfizer HIV-focused affiliate two novel mechanisms, one of which could be used in combination with Tivicay and another that addresses a different stage of the virus' lifecycle than any HIV drug now approved.

HIV Drug Sales Rescue GSK's Second Quarter

"Stand-out" sales of Tivicay and Triumeq validate GSK's decision earlier this year to hang on to its stake in ViiV Healthcare.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts